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Abstract
Background: Eluforsen (previously known as QR-010) is a 33-mer antisense oligonucleotide under develop-
ment for oral inhalation in cystic fibrosis (CF) patients with the delta F508 mutation. Previous work has shown
that eluforsen restores CF transmembrane conductance regulator (CFTR) function in vitro and in vivo. To be
effective, eluforsen has first to reach its primary target, the lung epithelial cells. Therefore, it has to diffuse
through the CF airway surface layer (ASL), which in CF is characterized by the presence of thick and viscous
mucus, impaired mucociliary clearance, and persistent infections. The goal of this study was to assess delivery
of eluforsen through CF-like ASL.
Methods and Results: First, air-liquid interface studies with cultured primary airway epithelial cells revealed
that eluforsen rapidly diffuses through CF-like mucus at clinically relevant doses when nebulized once or
repeatedly, over a range of testing doses. Furthermore, eluforsen concentrations remained stable in CF patient
sputum for at least 48 hours, and eluforsen remained intact in the presence of various inhaled CF medications
for at least 24 hours. When testing biodistribution of eluforsen after orotracheal administration in vivo, no
differences in lung, liver, trachea, and kidney eluforsen concentration were observed between mice with a CF-
like lung phenotype (ENaC-overexpressing mice) and control wild-type (WT) littermates. Also, eluforsen was
visualized in the airway epithelial cell layer of CF-like muco-obstructed mice and WT littermates. Finally,
studies of eluforsen uptake and binding to bacteria prevalent in CF lungs, and diffusion through bacterial
biofilms showed that eluforsen was stable and not absorbed by, or bound to bacteria. In addition, eluforsen was
found to be able to penetrate Pseudomonas aeruginosa biofilms.
Conclusions: The thickened and concentrated CF ASL does not constitute a significant barrier for delivery of
eluforsen, and feasibility of oral inhalation of eluforsen is supported by these data.
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Introduction
Eluforsen (previously known as QR-010) is an anti-sense oligonucleotide intended to treat cystic fibrosis
(CF) patients with the delta F508 mutation through oral in-
halation. Eluforsen is a 2¢O- Methyl modified, fully phos-
phorothioated 33-mer nucleotide single-stranded RNA
molecule complementary to the wild-type (WT) CF trans-
membrane conductance regulator (CFTR) mRNA. By re-
storing CFTR functionality in patients with the delta F508
mutation, eluforsen is intended to treat CF.
In CF, CFTR malfunctioning results in impaired chloride
efflux, mucus dehydration, that is, a higher percentage of
solids,(1) vulnerability to infections,(2) and chronic airway
inflammation. Current CF therapies are mainly focused on
lowering lung symptomatology by chest exercise, antibiot-
ics, mucolytics, corticosteroids, hydration of the mucus
(ex. inhaled hypertonic saline), and bronchodilators.(3) For
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several CFTR mutations, novel therapies have emerged,
which improve CFTR function at the protein level.(4–6)
Despite these efforts, CF patients are still burdened with
lung infections, exacerbations, and worsening of lung
function with increasing age, reflecting the need for better
therapies.
In a previous report, we have shown that eluforsen re-
stores chloride efflux in vitro in Ussing Chamber experi-
ments using primary human bronchial epithelial cells from
CF patients with the delta F508 mutation.(7) This response is
specific for eluforsen and is concentration dependent. In
addition, in vivo tests reveal that eluforsen normalizes sali-
vary CFTR-dependent secretion volume and nasal potential
difference (NPD) in delta F508 transgenic mice. Both saliva
secretion, as proxy for sweat-chloride test, and NPD assays
are clinically relevant and equivalent assays, which are
preclinical tests for the effectiveness of CFTR modulating
compounds.(8,9)
To be effective in restoring CFTR activity, eluforsen
first needs to reach its target, that is, the airway epithelial
cells, without being compromised. Effective delivery of
eluforsen in the CF airway surface layer (ASL) is there-
fore key for the development of eluforsen as a novel CF
therapy.
The ASL is characterized by the presence of two mucin-
rich layers, the mucus layer at the air interface and the
periciliary mucus layer (PCL), in direct contact with the
airway epithelium. Both layers contain a dense network of
highly glycosylated proteins, that is, mucins. While the
mucins in the mucus layer at the air interface are secreted
and transported out of the lung by mucociliary clearance, the
mucins in the PCL are tethered to the cilia and cell sur-
face.(10,11) Airway mucus contains a myriad of proteins,
cells, and molecules, which together with the ciliary move-
ment and mucin network function to prevent infections in the
lungs.
The ASL, especially that of CF patients, represents a
significant barrier for drug delivery. Compounds need to
remain stable in an infectious environment that contains
numerous immune cells and microorganisms. In addition, to
reach the cell surface, compounds must be able to diffuse
through the mucin-rich networks of the mucus layer and
PCL. For delivery of nucleic acid-based drugs across the
CF ASL, viral vectors,(12,13) liposomes,(14) and polymeric
nanoparticles(15–17) are being investigated. These carriers
aim at enhancing stability, improving diffusion through
mucin-rich networks. and increasing uptake in airway cells.
For antibiotics, liposomes are also being studied to penetrate
bacterial biofilms that are prevalent in CF.(14)
Carriers could introduce side effects such as immunoge-
nicity(18) can be difficult to produce in a controlled manner,
and have increased production costs. Having a nucleic acid-
based drug that remains stable and penetrates the ASL
without the need of a carrier is therefore preferable.
In this study, we describe a series of experiments that
tested delivery of ‘‘naked’’ eluforsen (without the use of a
carrier) through in vitro and in vivo CF-like airway mucus.
Also, stability of eluforsen in ex vivo CF sputum and
binding to/uptake in a selection of clinically relevant bac-
teria and bacterial biofilms was tested. Finally, stability of
eluforsen in the presence of commonly used inhaled CF
medications was studied.
Materials and Methods
In vitro diffusion of Cy5-labeled eluforsen
through CF-like mucus layers on air-liquid
interface cultures
For these experiments, primary airway epithelial cells
from ‘‘healthy’’ donor lungs, from the UNC Chapel Hill
Tissue Culture Facility, were used instead of cells from CF
patients. Culturing of both types of cells results in a mucus
layer that is thick and viscous (CF like). As a result, both
cell types are suitable to study the effect of thickened mucus
on eluforsen diffusion. Due to limited availability of pri-
mary cells from CF patients, diffusion through thickened
CF-like mucus was assessed in primary cells from ‘‘heal-
thy’’ donor lungs.
The lung epithelial cells were used to prepare air-liquid
interface (ALI) cultures according to a well-established
protocol that allows the formation of an endogenous mucus
layer.(19) The apical domain of these cultures was left un-
washed for a period of 2 weeks to accumulate mucus to a
CF-like phenotype consisting of more than 5% solids (wet-
to-dry weight ratio).(1) Normal mucus layers with less than
5% solids were obtained by nebulizing a small amount of
isotonic saline onto the mucus layers for hydration. For all
cultures, the % of solids was assessed before the diffusion
experiment as described previously.(20)
ALI cultures were placed in a temperature-, humidity-,
and CO2-controlled chamber outfitted with a low (nanoliter)-
volume nebulizer, and placed onto a stage of a confocal laser
scanning microscope (Leica SP5) in which XZ images could
be obtained. XZ images were obtained before and after 100
nL of (Cy5-labeled) eluforsen (Axolabs GmbH, Külmbach,
Germany) was nebulized onto the ALI culture apical surface
(1.1 cm2 surface area), in about 1 minute. For Cy5-labeled
eluforsen, the Cy5 label was conjugated to the 5¢end through
a peptidic (covalent) bond. The rate and the volume nebu-
lized reflect a deposition in the larger airways of humans
down to 2–6 generations [MPPD software(21)]. The nebulizer
was placed directly above the apical surface of the airway
cultures. Diffusion of eluforsen was studied in two different
experimental settings, as follows.
(A) Single-dose nebulization diffusion studies
ALI cultures with either a normal mucus layer with 2%–
5% solids or a CF-like mucus layer with 5%–11% solids
were made from primary lung epithelial cells from three
donors. Cy5-labeled eluforsen doses were nebulized onto
the cultures at 10, 50, or 100 lM. These doses were ex-
pected to be clinically relevant in the lungs based on
deposition modeling of eluforsen, with following as-
sumptions: a nebulization volume of 100 nL, a mucus
volume of 2–3 lL, and full uptake of eluforsen into the
mucus. The estimated eluforsen concentrations in the
mucus layers were confirmed to be clinically relevant by
an eluforsen Phase 1B clinical study.(22) For each dose
and mucus concentration, 2–7 individual cultures were
utilized. Before and directly following nebulization, XZ
images were taken of the mucus and cell layer with an
interval of 1–2 seconds. The resulting images for each
study were analyzed using custom-designed Matlab
software(23) for the diffusion velocity of the Cy5-labeled
eluforsen through the mucus layer, as described below.
(B) Multidose nebulization diffusion studies
ALI cultures reflecting a CF-like mucus layer with more
than 5% solids were established from primary lung epi-
thelial cells from three donors. A dose of 100 lM unla-
beled or Cy5-labeled eluforsen was nebulized onto the
cultures using the following protocols:
1. Single nebulization of unlabeled eluforsen or phosphate-
buffered saline (PBS) (control) followed by a 48-hour
interval and subsequent single nebulization of Cy5-
labeled eluforsen.
2. Four repeated nebulizations of unlabeled eluforsen or
PBS (control) with a 48-hour interval, and subsequent
single nebulization of Cy5-labeled eluforsen.
Three cultures from every donor were used (n = 9) for
each nebulization protocol. Before and directly following
nebulization of Cy5-labeled eluforsen, XZ images were ta-
ken of the mucus and cell layer and were analyzed as in the
single-dose studies. In this manner, the effect of a single or
four nebulizations of unlabeled eluforsen on subsequent
diffusion of Cy5-labeled eluforsen could be studied.
Diffusion of Cy5-labeled eluforsen was assessed by two
different methods:
1. Diffusion velocity: measurement of the speed at which
the edge of the Cy5-labeled eluforsen ‘‘band’’ moved
toward the epithelial cells (Matlab). Note: measure-
ment of diffusion velocity was not possible for the
10 lM Cy5-labeled eluforsen dose because the Cy5
fluorescence signal intensity was too low to track its
movement.
2. Time to reach 60% of the total Cy5-labeled eluforsen
signal localized at the level of the epithelial cells
(Matlab). In addition to diffusion velocity, we were
interested in measuring the time it takes for most of the
eluforsen to reach the actual cell surface. Here, we
measured the time it takes the Cy5-labeled eluforsen to
reach 60% of the maximum fluorescence intensity at
the PCL/cell interface.
The combination of both methods allowed a compre-
hensive investigation of the diffusion properties of elu-
forsen: (i) by studying the velocity of eluforsen movement
to its target, and (ii) by studying accumulation of Cy5-
labeled eluforsen at the cell surface of the target cells. Im-
ageJ and Matlab software were used to extract the images
and analyze the raw data. Nonparametric testing (Kruskal
Wallis, GraphPad) and post hoc testing (Tukey; GraphPad)
were applied to assess differences in diffusion velocity and
differences in time to reach 60% Cy5-labeled eluforsen
signal at the epithelial cell surface between different mucus
types and doses (experiment A) and between single and
repeated nebulization treatments (experiment B).
Stability of eluforsen in ex vivo CF sputum
Sputum was collected from CF patients at the UNC
Chapel Hill Pulmonary Clinic (March–October 2014) and
samples were kept at -80C until the start of the experiment.
All patients who provided sputum granted prior written
consent to participate in this study. All procedures employed
in this study conformed to the regulations put forth by the
UNC IRB. The mucus concentration of each sputum sample
was determined as previously described.(24) A total of 20
sputum samples were collected from 17 patients, and 14
collection periods (from March to October 2014, Table 1 for
detailed sample information, including medications used by
the patients). These 20 samples were used to prepare 7
pooled sputum samples for stability testing.
The samples were each divided into eight smaller aliquots
of *50 lL, of which four aliquots were spiked with elu-
forsen (Biospring, Frankfurt, Germany) to a concentration of
10 lg/mL and the four other aliquots were spiked with
eluforsen to a concentration of 100 lg/mL. These eluforsen
concentrations reflect the expected eluforsen levels in spu-
tum based on eluforsen deposition modeling, and were
confirmed in a Phase 1B clinical study of eluforsen.(22) After
spiking, one aliquot (from each of the two eluforsen con-
centrations) was frozen immediately, and the remaining
three aliquots were incubated for 12, 24, or 48 hours at 37C
to assess stability of eluforsen throughout time. After the
appropriate incubation, these samples were frozen and kept
at -80C until analysis. Unspiked CF sputum was used as
negative control.
Eluforsen concentrations were assessed by a dual hy-
bridization ELISA. For each sample, a serial dilution was
made in duplicate. In each plate, a standard curve of elu-
forsen was prepared in PBS and serially diluted in duplicate.
This serial dilution resulted in a sigmoidal curve from which
an EC50 value was determined with GraphPad software. For
Table 1. Sputum Sample Details
Sample
no. Medication used by patient
1 Tobramycin, dornase alfa, hypertonic saline,
inhaled steroids
2 Dornase alfa, azithromycin, inhaled steroids
3 Azithromycin, aztreonam, dornase alfa,
hypertonic saline, inhaled steroids
4 Azithromycin, aztreonam, hypertonic saline,
inhaled steroids
5 Hypertonic saline, inhaled steroids, dornase alfa
6 Hypertonic saline, inhaled steroids
7 Tobramycin, dornase alfa, hypertonic saline,
azithromycin
8 Aztreonam, dornase alfa, azithromycin, inhaled
steroids
9 Azithromycin, dornase alfa, hypertonic saline,
inhaled steroids
10 Tobramycin, dornase alfa, hypertonic saline,
azithromycin, inhaled steroids
11 Azithromycin, dornase alfa, inhaled steroids
12 Dornase alfa, azithromycin, inhaled steroids
13 Dornase alfa, hypertonic saline, inhaled steroids
14 Tobramycin, dornase alfa, hypertonic saline
15 Tobramycin, dornase alfa, hypertonic saline,
azithromycin, inhaled steroids
16 Tobramycin, aztreonam, dornase alfa, hypertonic
saline, azithromycin, inhaled steroids
17 Dornase alfa, hypertonic saline, azithromycin,
inhaled steroids




each sample, the EC50 was normalized against the EC50 of
the eluforsen standard curve on the same plate. These nor-
malized values were used to assess breakdown of eluforsen
by taking the t = 0 time point as 100% and comparing the
normalized values at time points t = 12, t = 24, and t = 48
hours against that 100% value. The dual hybridization
ELISA is based on the binding of complementary probes to
eluforsen, and subsequent detection of these probes. There-
fore, only degradation that affects probe binding can be de-
tected. This includes significant loss of nucleic acids, but not
minor chemical modifications. More details on the assay are
given in the Supplementary Data.
Stability of eluforsen in the presence of commonly
used inhaled CF medications
Dornase alfa (Pulmozyme 1mg/mL, 2500E), salbutamol
(5 mg/mL), fluticasone (1 mg/mL), n-acetylcysteine (100 mg/
mL), and aztreonam (Cayston 75 mg) were obtained from
the Haga hospital (Den Haag, The Netherlands) and were
stored according to the manufacturer’s conditions until the
start of the experiment. All CF medications and eluforsen
dilutions were made in 0.9% saline (VWR, The Netherlands).
Both the concentrations of the commonly used CF med-
ications and eluforsen are either expected clinical CF spu-
tum levels or observed CF sputum levels in patients.(22,25–28)
Dornase alfa at a concentration of 3 lg/mL, salbutamol at a
concentration of 2 lg/mL, fluticasone at a concentration of
5 lg/mL, n-acetylcysteine at a concentration of 100 mg/mL,
and aztreonam at a concentration of 6000 lg/mL were in-
cubated with one of following nominal eluforsen (Avecia,
Milford, MA) concentrations in saline: 10, 50, or 100 lg/mL.
In addition, samples containing CF medication only or con-
taining only eluforsen were used as controls. All samples were
aliquoted in triplicates of which one set of samples was frozen
immediately after preparation (t = 0), one set of samples was
incubated for 1 hour at 37C (t = 1 hour), and one set of samples
was incubated for 24 hours at 37C (t = 24 hours). After in-
cubation, samples were frozen and kept at -20C until analysis.
Eluforsen concentrations were assessed in duplicate by
Ion-Pairing Reversed Phase HPLC (IPRP-HPLC). Because
of the use of a reference standard, the IPRP-HPLC method
allows quantitation of eluforsen. In addition, the use of
impurity standards have shown that this method is also
stability indicating, that is, can detect breakdown products
of eluforsen, including chemical modification (oxidation).
Kruskal Wallis testing (GraphPad) was performed to as-
sess an overall effect of the CF medications on eluforsen
concentration over time.
Biodistribution of eluforsen in Scnn1b-Tg mice
with a CF-like lung phenotype
Age-matched, congenic C57BL/6N Scnn1b-Tg mice(29,30)
and WT littermates (breeding stock at UNC Chapel Hill,
NC) were housed under standard conditions, with access to
water and food ad libitum. Both males and females were
used for this study and mice were *6 weeks of age at the
start of the experiment. The experiment was approved by the
animal ethics committee of UNC Chapel Hill (US).
Scnn1b-Tg and WT mice received either a dose of
10 mg/kg eluforsen (produced at Avecia, Milford, MA) or
saline through orotracheal (OT) administration in a volume
of 25 lL (Table 2). Mice were dosed six times in total at
regular intervals over a 2-week period. The health status was
monitored by assessment of body weight, posture, and be-
havior. Tissues were processed for quantitative eluforsen
determination on the tissue level or for visualization of
eluforsen in lung tissue by in situ hybridization (ISH).
Quantitative eluforsen determination in trachea, lung, liver,
and kidneys. At 24 hours after final dosing, mice were an-
esthetized and sacrificed by exsanguination. The lungs were
lavaged with PBS to remove noninternalized eluforsen. The
trachea, lung, liver, and kidneys were then isolated by fine
dissection; organs were weighted, snap frozen in liquid ni-
trogen, and stored at -80C until further analysis. A hybrid-
ization HPLC assay (Axolabs, Germany) was used to assess
eluforsen concentration in the organs of WT and Scnn1b-Tg
mice. The lung, trachea, liver, and kidney from saline (n = 3)-
and eluforsen-treated mice (n = 6) were tested for eluforsen
concentration.
Kruskall Wallis testing (GraphPad) was performed to test
for an overall effect of the CF-like phenotype on eluforsen
concentration in the lung, trachea, liver, and kidney.
Eluforsen visualization through ISH in the lung. A sepa-
rate cohort of mice was used for visualization of eluforsen
by ISH. At 24 hours after final dosing, mice (n = 3/group)
were sacrificed by exsanguination. The pulmonary vascu-
lature was perfused with normal saline through injection in
the heart right ventricle. Lungs were inflation fixed with
10% neutral buffered formalin (NBF) at 25 cm H2O pres-
sure, ligated, removed from the chest cavity, and fixed for
24 hours at room temperature (RT). After removing the
fixative, the trachea and lung were first washed extensively
with tap water (10 min, thrice), followed by washing twice
with 50% EtOH, and once with 70% EtOH (Thermo Fisher
Scientific, Hampton, NH). The organs were embedded in
paraffin and cut into 5 lm thick slices.
To determine morphology of the tissue, a conventional
Hematoxylin/Phloxine/Saffron (HPS) staining (Sigma) was
performed on formalin-fixed, paraffin-embedded, lung sec-
tions of WT and Scnn1b-Tg mice, which were dosed with
saline or eluforsen. HPS distinguishes between muscle and
cytoplasm (pink), nuclei (purple), and connective tissue
(yellow) due to the addition of Saffron.
RNAscope (Advanced Cell Diagnostics) was utilized to
detect/localize eluforsen in the lung of Scnn1b-Tg and WT
mice. RNAscope is an ISH technology, which utilizes
custom-designed probes and signal amplification technology
to visualize ribonucleic acids. Before the hybridization,
Table 2. Animal Numbers Used for Eluforsen
Quantitation and Eluforsen Visualization
in Lung Tissue of Scnn1b-Tg Mice
and Wild-type Littermates
Eluforsen quantitation Eluforsen visualization
Saline Eluforsen Saline Eluforsen
Scnn1b-Tg 3 6 3 3
WT 3 6 3 3
WT, wild type.
broth at 37C for 1 or 5 days. Afterward, the filters containing
the biofilms were placed into a fresh transwell plate con-
taining 1 mL 0.9% saline. As control, empty filters without
bacterial biofilms were used. A single dose of 100 lL of Cy5-
labeled eluforsen (64 mg/mL; Axolabs GmbH, Külmbach,
Germany) was pipetted onto the upper compartment of bio-
film containing and control filters.
Diffusion of Cy5-labeled eluforsen was assessed by
measuring the Cy5 fluorescence in the basolateral medium
at different time points: t = 0, t = 15 min, t = 2 hours, t = 6
hours, t = 24 hours, and t = 48 hours. Before taking samples,
the transwell setup was slowly mixed by rotary motion.
A 10 lL sample from the medium was assessed for fluo-
rescence using a NanoDrop 3300 (Thermo Scientific).
Quantitative and qualitative assessment of eluforsen
The studies described here make use of several methods
to assess eluforsen stability and eluforsen concentrations:
hybridization HPLC, dual hybridization ELISA, IPRP-
HPLC, and IEX-HPLC. The choice of assay per experiment
is mainly based on the type of matrix eluforsen is in.
Complex biological matrixes such as sputum and tissue are
analyzed by means of hybridization-based assays, while less
complex matrixes such as mixtures of eluforsen with med-
ications or bacterial suspensions can be measured with
IPRP-HPLC or IEX-HPLC. Both the hybridization HPLC
and hybridization ELISA make use of probes that bind to
eluforsen in complex matrices, and subsequent quantitative
measurement of those probes. Alternatively, IPRP-HPLC
and IEX-HPLC methods rely on separation of eluforsen and
impurities from the matrix through chromatography. Im-
portantly, each of these methods is calibrated with a known
concentration of eluforsen in its appropriate buffer solution.
A detailed description of the methods used can be found in
the Supplementary Data.
Results
In vitro diffusion of Cy5-labeled eluforsen
through CF-like mucus layers on ALI cultures
To reach its primary target, the airway epithelial cells,
eluforsen has to diffuse through thick and viscous mucus
commonly associated with CF. A first study was performed
to assess diffusion velocity and the time it takes for most of
the Cy5-labeled eluforsen to reach the epithelial cell surface,
for different Cy5-labeled eluforsen doses in both normal and
CF-like mucus layers. A follow-up study determined the
effect of a single or four consecutive nebulizations of un-
labeled eluforsen on subsequent diffusion of Cy5-labeled
eluforsen in CF-like mucus layers. Figure 1 shows a repre-
sentative time course of eluforsen diffusion through the
mucus layer of an ALI culture.
(A) Single-dose nebulization diffusion studies
Figure 2A shows the diffusion velocity of Cy5-labeled
eluforsen through normal (2%–5% solids) and CF-like
mucus (5%–11% solids) for the different dose levels
nebulized. The diffusion velocity of Cy5-labeled eluforsen
ranged between *0.2 and *3 lm/sec, dependent on the
culture. There were no significant differences in diffusion
velocity between normal and CF-like mucus ( p = 0.16). In
tissue samples were pretreated according to the manufac-
turer’s instructions to block endogenous peroxidase activity 
and RNA retrieval to expose eluforsen. After 2 hours of 
hybridization with a specific eluforsen probe, the RNAscope 
2.0 HD Detection kit was used to visualize eluforsen. As 
negative control, a probe specific for DapB (dihydrodipi-
colinate reductase) was used, and as positive control a probe 
specific for Mm-Ubc (Mus musculus ubiquitin C) was used. 
The amplification system involved enzymatic detection with 
DAB (brown). Tissue slides were counterstained with He-
matoxylin (Sigma) and mounted with Pertex. A transmitted 
light microscope (Carl Zeiss Axiolab.A1) was used to image 
the lung tissue samples. Images were taken by ZEN software 
(Carl Zeiss).
Stability and uptake/binding of eluforsen
when in contact with CF-relevant microorganisms
As CF lungs can be colonized by many types of micro-
organisms, stability and binding/uptake of eluforsen to these 
bacteria were studied. A selection of three bacterial strains 
prevalent to CF were used, and were incubated separately 
with eluforsen (Avecia, Milford, MA), under the assumption 
that eluforsen binding to bacteria or uptake by bacteria 
would lead to the presence of eluforsen in the (bacterial) 
pellet after spinning down the suspension, and therefore 
decreasing eluforsen concentrations in the supernatant.
Pseudomonas aeruginosa (DSM29305), Staphylococcus 
aureus (ATCC 6538), and Burkholderia multivorans (ATCC 
BAA-247) were all purchased from ATCC and incubated at 
a concentration of 105 CFU/mL in the presence of 100 lg/mL 
eluforsen in synthetic nasal medium.(31) Controls contained 
bacteria only or eluforsen only (n = 2). Samples were mixed 
and immediately processed or incubated at 37C for 2, 6, or 
24 hours until processing. Processing involved spinning 
down the solutions (10 min at 10,000g) followed by collec-
tion of the supernatant and heat inactivation of the super-
natant (82C for 5 min). Stability studies of eluforsen have 
shown that this condition does not affect eluforsen integrity 
(data not shown). The supernatant was snap frozen in liquid 
nitrogen and stored at -80C until analysis.
An Ion-Exchange HPLC (IEX-HPLC) method was used 
to assess eluforsen concentrations and stability in the super-
natant fractions. Because of the use of a reference standard, 
the IEX-HPLC method allows quantitation of eluforsen. In 
addition, the use of impurity standards has shown that this 
method is also stability indicating, that is, can detect 
breakdown products of eluforsen, including chemical mod-
ification (oxidation).
Kruskal Wallis testing (GraphPad) was performed to as-
sess an overall effect of bacterial strains on eluforsen con-
centrations in the supernatant.
Diffusion of Cy5-labeled eluforsen
through P. aeruginosa biofilms
The CF lung can contain biofilms of microorganisms such 
as P. aeruginosa.(32) These biofilms are structures present in 
the mucus layer, and the potential influence of these struc-
tures on eluforsen diffusion was assessed. Triplicate biofilms 
were prepared on polycarbonate filters of transwell plates, 
using either P. aeruginosa (DSM29305) or P. aeruginosa 
(ATCC 700888), purchased from ATCC, in Tryptic soy
addition, there was no statistical difference between the
dose of Cy5-labeled eluforsen on the diffusion velocity
( p = 0.73). Figure 2B shows the time to reach 60% Cy5-
labeled eluforsen signal at the epithelial cells in normal
(2%–5% solids) and CF-like mucus (5%–11% solids) for
the different doses nebulized. There was a trend indicating
slower mass movement of Cy5-labeled eluforsen through
the CF-like mucus layer toward the epithelial cell layer,
but this was not statically significant ( p = 0.08). In addi-
tion, there was no significant effect of dose on the time to
reach 60% Cy5 signal at the epithelial cells ( p = 0.74).
(B) Multidose nebulization diffusion studies
Figure 3 shows the diffusion velocity and time to reach
60% Cy5-labeled eluforsen signal at the airway epithelial
cell surface in CF-like mucus (5%–11% solids) after
single versus repeated nebulizations of eluforsen. The
diffusion velocity and time to reach 60% Cy5 signal at the
epithelial cell layer were similar for 1, 2, or 5 (Cy5 la-
beled) eluforsen nebulizations ( p = 0.93 and p = 0.16 for
the diffusion velocity and time to reach 60% Cy5 signal,
respectively). Furthermore, the diffusion velocity and
time to reach 60% Cy5 eluforsen signal at the epithelial
cells were similar for both single and repeated nebuliza-
tion experiments ( p = 0.90 and p = 0.85 for the diffusion
velocity and time to reach 60% Cy5 signal, respectively).
Stability of eluforsen in ex vivo CF sputum
Besides being able to diffuse through the CF lung mucus,
eluforsen also has to remain stable. Stability of eluforsen in
FIG. 1. Representative XZ images of Cy5-labeled eluforsen (red; 100 lM) diffusion through a normal in vitro mucus
layer. Green indicates time course of Cy5-labeled eluforsen (red) diffusion through calcein-stained cells. Images go from
upper left to lower right. Time between pictures is 2 seconds each.
FIG. 2. Diffusion velocity (A) and time to reach 60% Cy5-labeled eluforsen signal at the
epithelial cells (B) for normal (2%–5% solids) and CF-like (5–11% solids) mucus; light
gray bars indicate the 10 lM Cy5-labeled eluforsen dose, dark gray bars indicate the 25 lM
Cy5-labeled eluforsen dose, and black bars indicate the 100 lM Cy5-labeled eluforsen
dose. Bars indicate averages of 2–7 individual ALI cultures, error bars represent standard
deviation. CF, cystic fibrosis; ALI, air-liquid interface.
sputum obtained from CF patients, indicated by eluforsen
concentrations measured by dual hybridization ELISA, was
therefore assessed for up to 48 hours.
Figure 4 shows the relative eluforsen concentrations
compared to t = 0 during the 48-hour incubation in CF
sputum. Overall, the sputum constituents (mucus, bacteria,
inflammatory cells, etc.) did not significantly affect elu-
forsen concentration through this time course ( p = 0.80).
Control unspiked sputum samples did not show any signal in
the hybridization ELISA.
Stability of eluforsen in the presence
of commonly-used inhaled CF medications
CF patients are treated with various inhaled medications
to treat CF symptomology. Stability of eluforsen when ex-
posed to these medications for up to 24 hours was therefore
assessed.
Clinically relevant levels of medications and clinically
relevant eluforsen concentrations were used. Figure 5 shows
the relative eluforsen concentrations versus t = 0 at 1 and
24 hours of incubation in the presence of different inhaled
CF medications: dornase alfa, salbutamol, fluticasone, n-
acetylcysteine, and aztreonam. Relative eluforsen concen-
trations were unchanged in the presence of the medications
for all tested time points, independent of the eluforsen
concentration used ( p ‡ 0.05 for all medications). Also,
chromatograms showed that eluforsen integrity was main-
tained in the presence of the different inhaled CF medica-
tions, showing no changes in full-length product and
impurity profiles.
Biodistribution of eluforsen in Scnn1b-Tg mice
with a CF-like lung phenotype
To determine the effect of an airway muco-obstructive,
CF-like phenotype on eluforsen delivery in vivo, Scnn1b-Tg
mice were repeatedly dosed through OT administration with
eluforsen or saline (10 mg/kg). Biodistribution of eluforsen,
together with localization of eluforsen in the lung was
studied after last dosing. After 2-week OT administration of
eluforsen or saline, mice were sacrificed and tissues were
processed for either eluforsen quantification or eluforsen
visualization by ISH. Figure 6 shows eluforsen concentra-
tions in different organs collected from the Scnn1b-Tg mice
and WT littermates. There was no overall effect of CF-like
phenotype on eluforsen concentration in the organs ( p = 0.89).
Eluforsen concentrations in lung and trachea were unaffected
by the mucus hyperconcentration/stasis exhibited by Scnn1b-
Tg mice. Eluforsen was also detected in extrapulmonary
organs, that is, liver and kidney. Eluforsen was not detected
in the organs of saline-treated mice.
FIG. 3. Diffusion velocity (A) and time to reach 60% Cy5-labeled eluforsen signal at the
epithelial cells (B) for CF-like mucus after different nebulization protocols; 1. PBS neb-
ulization, followed by Cy5-labeled eluforsen nebulization 48 hours later (black bar), 2.
eluforsen nebulization followed by Cy5-labeled eluforsen nebulization 48 hours later (gray
checkered), 3. four times PBS nebulization with a 48-hour interval, followed by Cy5-
labeled eluforsen nebulization (black horizontal stripes), and 4. four times eluforsen neb-
ulization with a 48-hour interval followed by Cy5-labeled eluforsen nebulization (black
vertical stripes). Bars indicate averages of nine individual ALI cultures, error bars indicate
standard deviation. PBS, phosphate-buffered saline.
FIG. 4. Stability of eluforsen in the presence of CF spu-
tum (2%–5% solids) at 10 lg/mL concentration (gray bars)
and 100 lg/mL concentration (black bars). Bars represent
the average of seven sputum samples, error bars indicate
standard deviation.
Figure 7 shows representative histology and ISH micro-
graphs of saline-treated WT and Scnn1b-Tg mice. A clear
difference in morphology of the alveoli was observed, with
the Scnn1b-Tg mice exhibiting alveolar space enlargement,
as previously reported.(33) In addition, the airway lumen of
the Scnn1b-Tg mice contained macrophages and mucus
plugs. The lumen of WT mice did not contain mucus plugs.
Importantly, ISH for eluforsen was negative in saline-treated
control mice.
For WT and Scnn1b-Tg mice treated with eluforsen,
Figure 8 shows representative histology and ISH results.
Regarding eluforsen treatment, both WT and Scnn1b-Tg
mice showed presence of eluforsen in the lung epithelial cell
layer. For both WT and Scnn1b-Tg mice treated with elu-
forsen, an inflammatory cell infiltrate was observed, which
was strongly positive for eluforsen. Histologically, the
composition of this infiltrate appeared mostly macrophagic.
Preliminary bronchoalveolar lavage (BAL) analysis also
suggests a neutrophilic component in both WT and Scnn1b-
Tg mice treated with eluforsen (data not shown).
Stability and uptake/binding of eluforsen
when in contact with CF-relevant microorganisms
A major limitation of the Scnn1b-Tg model is the absence
of chronic lung infections, which are characteristic for
CF.(34) To assess the potential impact of CF lung microor-
ganisms on delivery of eluforsen, eluforsen stability was
assessed after incubation with P. aeruginosa, B. multivorans,
or S. aureus for up to 24 hours. Samples were spun down and
the supernatant was tested for eluforsen concentration and
integrity. Figure 9 shows the eluforsen concentrations in the
supernatant of these samples (eluforsen that is not bound or
taken up by bacteria). No significant differences in eluforsen
concentrations were observed in the supernatants compared
to control samples where no bacteria were added ( p = 0.55).
In addition, no degradation product peaks were observed in
the IEX-HPLC chromatograms, indicating maintenance of
eluforsen integrity.
Diffusion of Cy5-labeled eluforsen
through a P. aeruginosa biofilm
Two P. aeruginosa strains were cultured in a biofilm ei-
ther 1- or 5-day old, after which diffusion of Cy5-labeled
eluforsen through these biofilms was assessed. Figure 10
shows the cumulative Cy5 signal in the medium (acceptor)
side of the setup for up to 48 hours after application of Cy5-
labeled eluforsen on top of the biofilm or control filters.
Compared to control (filter only), Cy5-labeled eluforsen pas-
sage through the biofilm was retarded in both P. aeruginosa
biofilms. However, after 15 minutes, a Cy5 signal in the ac-
ceptor side could be observed for all groups.
FIG. 5. Relative eluforsen concentrations compared to t = 0 when incubated with dornase alfa (3 lg/mL) (A), salbutamol
(2 lg/mL) (B), fluticasone (5 lg/mL) (C), N-acetylcysteine (100 mg/mL) (D), and aztreonam (6000 lg/mL) (E) for 24
hours. Striped bars show relative eluforsen concentrations in the presence of medication. Bars represent an average of four
measurements, error bars indicate the standard deviation.
FIG. 6. Eluforsen concentrations in the lung, trachea, li-
ver, and kidneys of Scnn1b-Tg (gray bars) and WT mice
(black bars) treated with eluforsen (n = 6), measured at 24
hours after the last dose. WT, wild type.
Discussion
Eluforsen is an oligonucleotide under development as a
therapeutic for CF patients with the delta F508 mutation,
and is intended for oral inhalation through nebulization. The
aim of these studies was to assess whether eluforsen could
penetrate the CF lung ASL, remain stable, and ultimately be
taken up by the airway epithelium. Because the ASL in CF
is composed of multiple components (mucins, DNA, and
inflammatory cells), which might inhibit diffusion of elu-
forsen, bind to eluforsen, and/or potentially affect stability
of eluforsen, multiple studies were executed that focused on
different barriers present in the CF ASL.
A first set of experiments studying diffusion kinetics of
Cy5-labeled eluforsen through an in vitro CF-like mucus
layer showed that eluforsen achieves a high diffusion ve-
locity through the ASL, reaching the airway epithelial cells
within minutes. This high diffusion velocity was observed
for different Cy5-labeled eluforsen dose levels, and for
single and repeated nebulization of eluforsen. While a
(small) trend toward slower diffusion of Cy5-labeled elu-
forsen in CF-like mucus layers compared to normal mucus
FIG. 7. ISH; (A–D) 5 · objective and (E–H) 40 · objective of HPS (A, B,
E, F) and ISH (C, D, G, H) of lung sections of Scnn1b-Tg and WT mice,
which were treated with saline (n = 3). (A, B, E and F) show HPS staining,
where nuclei are shown in dark purple (hematoxylin), cytoplasm is shown in
pink (phloxine), and connective tissue is yellow (saffron). (C, D, G and
H) show the same organ section subjected to ISH staining, wherein nuclei
are stained in light purple (hematoxylin) and eluforsen is show in brown.
Black arrows (A, Scnn1b-Tg) point out mucus plugs and macrophages in
the lumen of bronchi. HPS, Hematoxylin/Phloxine/Saffron; ISH, in situ
hybridization.
layers was present, this was not significantly different.
However, even if diffusion through CF-like mucus might be
a little slower, Cy5-labeled eluforsen still penetrates this
type of mucus very fast, considering that nebulization of an
eluforsen dose is *10 minutes, while diffusion through the
CF ASL is likely a few minutes.
In these set of experiments, diffusion of eluforsen was
assessed based on movement of the conjugated Cy5 label.
Other methods such as fluorescence recovery after photo-
bleaching (FRAP) also have been used to study diffusion of
molecules through mucus.(35) Although both methods have
been shown to be complementary,(35) it was challenging to
perform FRAP experiments with Cy5-labeled eluforsen.
This dataset strongly supports that eluforsen easily mi-
grates through the mucin network that is present in the CF
mucus layer and in the PCL. Easy diffusion through these
FIG. 8. ISH; (A–D) 5 · objective and (E–H) 40 · objective of HPS (A, B,
E, F) and ISH (C, D, G, H) of lung sections of Scnn1b-Tg and WT mice,
which were treated with 10 mg/kg eluforsen (n = 3). (A, B, E and F) show
HPS staining, where nuclei are shown in dark purple (hematoxylin), cyto-
plasm is shown in pink (phloxine), and connective tissue is yellow (saffron).
(C, D, G and H) show the same organ section subjected to ISH staining,
wherein nuclei are stained in light purple (hematoxylin) and eluforsen is
shown in brown.
networks might be explained by the high negative charge of
eluforsen, which could repel the also negatively charged
mucin network.(36) Nonetheless, Hanes and colleagues have
also shown that negatively charged molecules might interact
with negatively charged mucins, by binding to positively
charged molecules such as proteins.(37) Importantly, elu-
forsen has a hydrodynamic radius of *3 nm, which is small
enough to pass through the mucin pores,(38) and small en-
ough to penetrate the PCL mesh that can filter out particles
larger than 5 nm (i.e., viral vectors and liposomes).(20)
In these studies, a fluorescent label was used to track
eluforsen through the in vitro mucus layer. This label (Cy5)
makes up *10% of the total weight of the Cy5-labeled
eluforsen complex, and makes eluforsen slightly more li-
pophilic. During diffusion studies, a few normal and CF
mucus layers were also nebulized with Cy5 only to assess
diffusion properties of this label without being conjugated to
eluforsen. The diffusion velocity of Cy5 only was slightly
higher compared to Cy5-labeled eluforsen (data not shown).
Both size and lipophilicity could affect diffusion through
the mucus layer. Size is an important parameter since the
mucin network is known to increasingly hamper the diffu-
sion of molecules with increasing size.(39) Following this
reasoning, conjugation of Cy5 to eluforsen might cause a
lower diffusion rate compared to unlabeled eluforsen (and
Cy5 label only) by increasing its size. Regarding lipophili-
city, it is known that mucus can pose a barrier to lipophilic
drugs.(40) The reasoning is that mucus is a complex hydro-
gel, and compounds need to be water soluble to pass through
this hydrogel. As such, conjugation of Cy5 to eluforsen might
lower diffusion compared to unlabeled eluforsen through CF-
like mucus, as tested here.
Nonetheless, despite potential impact of Cy5 on eluforsen
diffusion through CF-like mucus, the diffusion data obtained
in these experiments strongly suggest that the CF lung layer
is not a barrier in terms of diffusion through the mucin net-
work. Mucus fractions collected after finalization of the ex-
periments were tested with hybridization HPLC to confirm
the presence of intact Cy5-labeled eluforsen, and therefore
ensuring stability of the Cy5 label conjugated to eluforsen.
In addition to being able to diffuse quickly through air-
way mucus, eluforsen also has to remain stable in the CF
FIG. 9. Eluforsen concentrations in the supernatant of control solution (gray bars) and in
supernatants of bacterial suspensions of Pseudomonas aeruginosa (striped bars), Bur-
kholderia multivorans (checkered bars), and Staphylococcus aureus (dotted bars). Bars are
averages of two measurements, error bars indicate standard deviation.
FIG. 10. Fluorescence signal at acceptor side after applying Cy5-labeled eluforsen to
either a 1-day biofilm (A) or 5-day-old biofilm (B). Black lines indicate a biofilm composed
of P. aeruginosa ATCC700888, dark gray lines indicate a biofilm composed of
P. aeruginosa DSM 29305, and light gray lines correspond to control filters without
biofilm.
mucus environment. For that reason, we studied eluforsen
stability when in contact with sputum from CF patients,
which is enriched in proteolytic activities, and when in
contact with commonly inhaled CF medications, which in-
clude DNAse. Results show that eluforsen concentrations
remained unchanged for at least 48 hours in CF sputum, and
that eluforsen remains stable when incubated for at least 24
hours with clinically relevant levels of inhaled CF medica-
tions. Concerning the stability of eluforsen in sputum, a
maximum of 48 hours of incubation was tested. Since sputum
rapidly breaks down ex vivo due to the abundance of pro-
teases,(41) the sputum matrix could only be used for this time
frame until it was completely liquified. Nonetheless, it could
be argued that this liquified sputum is still a harsh envi-
ronment, since the sputum components such as mucins and
proteases are still present. The increase in variability of
eluforsen concentration over the 48-hour timeframe likely
reflects differences in sputum breakdown and therefore
difference in this matrix. Of note, a hybridization ELISA
was used to study eluforsen stability in sputum. This method
is suitable to measure eluforsen concentrations in difficult
matrixes such as CF sputum, compared to nonprobe-based
HPLC methods that require extensive sample cleanup. The
hELISA relies on the binding of complementary probes to
eluforsen. These probes will still bind to eluforsen in case of
small modifications or degradation of eluforsen (nucleic
acid loss and chemical modification), although perhaps with
lower binding affinity. Therefore, this method is suitable to
assess significant loss of nucleic acids, but not for detecting
minor chemical modifications.
Concerning the stability of eluforsen in the presence of
clinically relevant levels of inhaled CF medications, IPRP-
HPLC results show no indication of stability issues as elu-
forsen concentrations remained the same throughout testing.
These data indicate that CF sputum and inhaled CF medi-
cations do not affect eluforsen stability in the lungs of CF
patients.
Bioavailability of eluforsen was assessed in Scnn1b-Tg
mice and control littermates. Eluforsen was given through
OT administration, and distribution of eluforsen in the lung,
trachea, liver and kidney was assessed. Previous studies
with eluforsen have shown that after OT administration in
conventional mice, eluforsen can be detected in the liver and
kidney.(7) The kidney and liver are organs known for their
accumulation of antisense oligonucleotides, and presence of
eluforsen in those organs implies eluforsen being taken up in
the blood, either through pulmonary or gastrointestinal (GI)
pathways. Results show that eluforsen concentrations in the
lung, trachea, liver and kidney are similar between mice with a
CF-like lung phenotype and control littermates. Also, ISH
showed eluforsen localized in the lung tissue, and could be
observed in the epithelial cell layer. This shows that eluforsen
reaches its target and is strong evidence that in a living or-
ganism with a CF-like lung environment, eluforsen is capable
of diffusing through the concentrated mucus layer of the ASL
and taken up by lung tissue. In addition, eluforsen concentra-
tions in lung, trachea, liver, and kidney were similar between
Scnn1b-Tg and control mice, indicating that a dehydrated
airway surface does not lower bioavailability of eluforsen.
Since the Scnn1b-Tg mouse model is a well-established
model reflecting CF lung characteristics such as increased
mucus concentration, PCL collapse, and airway inflamma-
tion,(29,30) these data are very strong indication that similar
characteristics in CF patient lungs will not impair delivery
and bioavailability of eluforsen. A major limitation of the
Scnn1b-Tg model is the absence of chronic lung infections,
which are characteristic for CF.(34) To assess the potential
impact of CF lung microorganisms on eluforsen delivery,
eluforsen was first exposed to different bacterial strains
prevalent in CF lungs, and its stability and potential bacte-
rial binding/uptake assessed. Three bacterial species were
chosen based on their relative abundance in CF lung or
pathogenicity, that is, P. aeruginosa, B. multivorans, and S.
aurus. Eluforsen was incubated with each of these bacterial
species individually to assess uptake/binding and stability of
eluforsen when coming in contact with these microorgan-
isms. Results show that incubation of eluforsen with these
bacteria does not affect eluforsen concentration and stabil-
ity, and that uptake and binding are not relevant for the
eluforsen and bacterial concentrations tested. Both the elu-
forsen and bacterial concentration used were clinically rel-
evant,(22,42,43) suggesting that eluforsen concentration and
integrity when exposed to these bacteria in the lungs of CF
patients would not affect its effectivity. Next, we showed
that bacterial biofilms of P. aeruginosa did not hamper dif-
fusion of eluforsen. Cy5-labelled eluforsen diffuses through
the biofilms as quickly as 15 minutes after administration.
However, compared to control (filter only), Cy5-labelled
eluforsen passage through the biofilm was retarded in both 1-
and 5-day-old P. aeruginosa biofilms. This indicates either
that the diffusion velocity of Cy5-labeled eluforsen is slower
compared to controls or that a part of Cy5-labeled eluforsen
is retained in the biofilm. While further studies are needed to
assess the extent of impaired eluforsen movement through
bacterial biofilms of P. aeruginosa, or other bacteria, these
results are encouraging. They show that, in principle,
eluforsen can pass through the complex biological matrix
formed by bacteria.
The studies described here show that the CF ASL does
not constitute a significant barrier for delivery of ‘‘naked’’
eluforsen to its primary target; (i) eluforsen diffuses quickly
through CF-like mucus in vitro upon single and repeated
nebulization, (ii) it remains stable in CF sputum and in the
presence of inhaled CF medications, (iii) a CF-like lung
phenotype does not affect lung distribution and eluforsen
bioavailability in (extrapulmonary) tissues, and (iv) bacteria
prevalent in CF do not affect stability, although they might
lower diffusion of eluforsen. Clinical data from a phase 1B
study with eluforsen support our findings that the CF ASL is
no barrier for delivery through oral inhalation.(22)
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